Go Pro
→ The rich already moved their money (From Parkview Capital Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$90.92
-7.7%		$42.47
$10.94
▼
$104.00
$5.71B2.021.11 million shs921,031 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+3.86%+196.39%+165.68%+155.47%+524.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$90.92
-7.7%		$42.47
$10.94
▼
$104.00
$5.71B2.021.11 million shs921,031 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+3.86%+196.39%+165.68%+155.47%+524.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$100.438.87% Upside

Current Analyst Ratings Breakdown

Latest BSE, RBW, KOD, and PYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$103.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$112.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$85.00 ➝ $145.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $120.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$58.00 ➝ $96.00
9/24/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$36.00
9/24/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$36.00
9/17/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$58.00
8/17/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$58.00
8/3/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$56.00 ➝ $66.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.97 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.19N/AN/AN/AN/A-273.23%-85.48%11/12/2026 (Estimated)

Latest BSE, RBW, KOD, and PYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.9565-$1.05-$0.0935-$1.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
2.49
2.49

Institutional Ownership

CompanyInstitutional Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%

Insider Ownership

CompanyInsider Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
12462.85 million34.94 millionOptionable

Recent News About These Companies

Show Me The Money: Kodiak Sciences Shares Deliver More Than 500% Return In Just Over A Year
October 2 at 6:31 AM  |  rttnews.comhttps://www.rttnews.com/3696099/show-me-the-money-kodiak-sciences-shares-deliver-more-than-500-return-in-just-over-a-year.aspx?type=ts
Kodiak Sciences (NASDAQ:KOD) Stock: Insider Bros. Advisors Lp Baker Purchases 33,726 Shares
October 2 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077675
Brokers Set Expectations for Kodiak Sciences FY2027 Earnings
October 2 at 2:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076744
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
October 1 at 7:22 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kodiak-sciences-more-doubles-eye-145736586.html
Kodiak Sciences (NASDAQ:KOD) Stock Price Up 5.2% After Insider Buying Activity
October 1 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-kodiak-sciences-nasdaq-kod-stock-price-up-52-after-insider-buying-activity-2026-10-01/
Kodiak Sciences (NASDAQ:KOD) Sees Unusually-High Trading Volume on Analyst Upgrade
October 1 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071920
Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Buys 33,726 Shares of Stock
September 30 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-kodiak-sciences-nasdaq-kod-director-bros-advisors-lp-baker-buys-33726-shares-of-stock-2026-09-30/
Insider Buying: Kodiak Sciences (NASDAQ:KOD) Director Buys $60,529,244.82 in Stock
September 30 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-buying-kodiak-sciences-nasdaq-kod-director-buys-6052924482-in-stock-2026-09-30/
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
September 30 at 8:05 AM  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/a-32-biotech-became-a-90-biotech-overnight-is-it-too-late-to-buy-kodiak/?utm_source=snapi
FY2027 EPS Estimate for Kodiak Sciences Lowered by Analyst
September 30 at 7:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-fy2027-eps-estimate-for-kodiak-sciences-lowered-by-analyst-2026-09-30/
Kodiak Sciences (NASDAQ:KOD) Stock Sees Unusually High Put Option Buying
September 30 at 5:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068502
Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing
September 30 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067389
Kodiak Sciences (NASDAQ:KOD) Stock Gets Price Target Boost from Lifesci Capital
September 30 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067391
Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, UBS Group Analyst Says
September 30 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067384
Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, HC Wainwright Analyst Says
September 30 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067388
Top Biotech Stocks To Research - September 28th
September 30 at 1:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31066918
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
September 29 at 12:16 PM  |  zacks.comhttps://www.zacks.com/stock/news/2997593/kod-stock-soars-178-on-positive-wet-amd-data-as-bla-filing-nears?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2997593
Kodiak Sciences (NASDAQ:KOD) Sees Strong Trading Volume After Analyst Upgrade
September 29 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-kodiak-sciences-nasdaq-kod-sees-strong-trading-volume-after-analyst-upgrade-2026-09-29/
Mid Cap Stocks To Consider - September 28th
September 29 at 7:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063969
Biotech Stock Kodiak Sciences (Nasdaq: KOD) Leads Nasdaq's Monday Gainers; up 177%
September 29 at 4:03 AM  |  investorideas.comI
Why Kodiak Sciences Skyrocketed Today
September 28, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/28/why-kodiak-sciences-skyrocketed-today/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Microscope and test tubes beside a laptop showing a rising chart signal biotech progress and improving stock momentum.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
By Chris Markoch | September 13, 2026
Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$90.92 -7.54 (-7.66%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas